FDA review: Statins don't raise risk of Lou Gehrig's disease

09/29/2008 | Reuters

An FDA analysis of 41 long-term controlled clinical studies did not find increased incidence of Lou Gehrig's disease -- amyotrophic lateral sclerosis -- in patients who took cholesterol-lowering statins compared with those who got placebo. An FDA official said the result was "reassuring" but recommended continued research into the safety of such drugs for ALS patients.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC